Company Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 223.62 USD | +2.49% |
|
+3.05% | +11.79% |
| 03:23pm | Charles River Laboratories International, Inc. Enters Manufacturing Collaboration with Gazi University | CI |
| 02:24pm | Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday | MT |
Business description: Charles River Laboratories International, Inc.
- discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;
- development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ;
- development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies.
Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%).
Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Number of employees: 19,400
Sales by Activity: Charles River Laboratories International, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Discovery and Safety Assessment (DSA) | 1.84B | 2.11B | 2.45B | 2.62B | 2.45B |
Research Models and Services (RMS) | 571M | 690M | 739M | 792M | 829M |
Manufacturing Solutions (Manufacturing) | 515M | 742M | 790M | 721M | 769M |
Geographical breakdown of sales: Charles River Laboratories International, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States (U.S) | 1.63B | 1.93B | 2.34B | 2.35B | 2.24B |
Europe | 829M | 1.04B | 1.03B | 1.08B | 1.08B |
Canada | 306M | 339M | 399M | 487M | 482M |
Asia Pacific | 155M | 223M | 193M | 201M | 197M |
Other | 6.13M | 7.29M | 9.96M | 16.85M | 52.82M |
Executive Committee: Charles River Laboratories International, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 75 | 31/12/1991 |
Michael Knell
DFI | Director of Finance/CFO | 49 | 28/09/2025 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 11/01/2026 |
Mark Mintz
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/2021 |
Julie Frearson
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2013 |
Composition of the Board of Directors: Charles River Laboratories International, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 31/12/1999 |
Martin MacKay
BRD | Director/Board Member | 69 | 04/07/2017 |
Virginia Wilson
BRD | Director/Board Member | 70 | 30/09/2019 |
Nancy Andrews
BRD | Director/Board Member | 67 | 27/02/2020 |
George Llado
BRD | Director/Board Member | 60 | 15/10/2020 |
Craig Thompson
BRD | Director/Board Member | 73 | 02/12/2013 |
| Director/Board Member | 53 | 21/01/2024 | |
Steven Barg
BRD | Director/Board Member | 64 | 19/05/2025 |
Mark Enyedy
BRD | Director/Board Member | 62 | 19/05/2025 |
Abraham Ceesay
BRD | Director/Board Member | 48 | 19/05/2025 |
Company details: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
251 Ballardvale Street
01887, Wilmington
+781 222 6000
http://www.criver.com
Group companies: Charles River Laboratories International, Inc.
| Name | Category and Sector |
|---|---|
Charles River Laboratories India Pvt Ltd.
Charles River Laboratories India Pvt Ltd. Manufactures pharmaceutical and biotechnology products | |
Charles River UK Ltd.
Charles River UK Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on biotechnology |
Miscellaneous Commercial Services
|
Charles River Laboratories Luxembourg SARL
Charles River Laboratories Luxembourg SARL Provides laboratory testing and research services | |
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research models and laboratory animal support services |
Miscellaneous Commercial Services
|
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research models and laboratory animal support services |
Miscellaneous Commercial Services
|
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.49% | +3.05% | +31.32% | -11.70% | 10.74B | ||
| +2.08% | -0.65% | -2.77% | +12.00% | 48.34B | ||
| +2.54% | -0.76% | +16.44% | +4.71% | 39.8B | ||
| +2.36% | -1.43% | +56.28% | +27.06% | 36.99B | ||
| -1.45% | -7.69% | +17.41% | +37.09% | 30.67B | ||
| +0.81% | -3.21% | +192.16% | +326.97% | 22.47B | ||
| +1.42% | -0.56% | +76.39% | +155.93% | 16.97B | ||
| Average | +1.44% | -2.66% | +55.32% | +78.86% | 29.43B | |
| Weighted average by Cap. | +1.49% | -3.10% | +44.11% | +62.01% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
- Company Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















